K&F’s first post-pandemic jury trial resulted in a $10.6 million verdict for the widow of a mesothelioma victim.

Type 2 diabetes medication could lead to serious drug injuries

Many Ohio residents suffer from type 2 diabetes. If you are one of them, your doctor may prescribe a medication to help control your condition. The problem is that some medications, such as Actos, cause serious drug injuries. If you take this particular medication, you could suffer harm. This is not the only medication that could cause harm because it is unsafe, but it is one that everyone is aware of that can cause significant health issues.

The generic name for Actos is pioglitazone. This medication has been linked to cases of bladder cancer. Research indicates that taking this medication for at least one year increases your chances of contracting this type of cancer by 40 percent. If you have already suffered from bladder cancer, you have a 40 percent chance that it will recur.

In response to this determination, the Food and Drug Administration issued a warning regarding the medication. Even so, when other countries heard about the danger, they simply took it off the shelves altogether. If you have taken this medication for at least one year and begin suffering from painful urination, blood in your urine and frequent urination, along with the feeling of having to urinate, but you cannot, then you may want to see your doctor.

Like other defective and dangerous medications, Actos manufacturers failed to warn anyone of the danger. Many people here in Ohio and elsewhere suffered serious drug injuries before any warnings were issued. Even if you do not take Actos, you could be taking another dangerous or defective medication that causes you harm. If you suspect this to be the case, you may benefit from a case evaluation to determine your rights and legal options.

Archives

$120 Million Settlement

To 15,000 Asbestos Victims

$20 Million Verdict

Mesothelioma

$17 Million Verdict

Mesothelioma

$8.2 Million Verdict

Mesothelioma

White Paper Read Now2
White Paper Read Now